The strong 2-year durability and safety data significantly de-risk 4D-150 ahead of Phase 3 readouts. Monitor enrollment updates and interim data from the 4FRONT trials; stock likely to re-rate on this catalyst.
Price Chart
Executive Summary
4D Molecular Therapeutics reported positive 2-year data from the PRISM Phase 2b trial of 4D-150 in wet AMD, showing 78% treatment burden reduction in the overall cohort and 87% in recently diagnosed patients, with a favorable safety profile. The data supports the ongoing 4FRONT Phase 3 program and de-risks the lead pipeline asset.
Key Facts
- Phase 2b trial (n=45) showed 78% reduction in supplemental injections vs. on-label aflibercept 2 mg Q8W (2.7 vs 12.0 mean injections over 2 years) in the overall cohort.
- Recently diagnosed subgroup (n=15) achieved 87% treatment burden reduction (1.6 vs 12.0 mean injections).
- Safety: 2.8% (2/71) mild transient intraocular inflammation within first 28 weeks; no new inflammation with 2-4+ years follow-up; no serious ocular adverse events.
- 3E10 vg/eye dose selected for Phase 3 4FRONT trials; dose response maintained through 2 years.
- Consistent maintenance of best corrected visual acuity (BCVA) and central subfield thickness (CST) control.
Financial Impact
No financial data in filing; positive clinical data supports Phase 3 advancement and potential multi-billion-dollar wet AMD market opportunity.
Risk Factors
- Phase 3 failure or inferior efficacy vs. standard-of-care anti-VEGF agents.
- Competition from approved therapies (aflibercept, faricimab) and other gene therapies in development.
- Regulatory and manufacturing risks for gene therapy product.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-308409 |
| Document: 0001193125-26-308409-index-headers.html | 0001193125-26-308409 |
| Document: 0001193125-26-308409-index.html | 0001193125-26-308409 |
| Document: 0001193125-26-308409.txt | 0001193125-26-308409 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 4w ago | Insider Cluster | $15.00 $14.71 | ▲ +1.93% | ▲ +1.85% | $11.03 (+26.47%) |
Aug 21, 2026 9w ago | Insider Cluster | $15.39 $15.72 | ▲ +2.14% | ▲ +1.82% | $11.03 (−28.33%) |
Jul 20, 2026 14w ago | 8-K | $11.09 $11.38 | ▲ +2.57% | ▲ +1.74% | $11.03 (−0.54%) |
Jul 18, 2026 14w ago | Press Release | $11.09 $11.38 | ▲ +2.57% | ▲ +1.74% | $11.03 (−0.54%) |
Jul 5, 2026 16w ago | Institutional Cluster | $12.72 $12.82 | ▲ +0.79% | ▲ +1.26% | $11.03 (−13.29%) |
Jun 29, 2026 17w ago | 8-K | $12.88 $13.30 | ▲ +3.26% | ▲ +2.48% | $11.03 (−14.36%) |
May 14, 2026 23w ago | EFFECT | $9.81 $9.15 | ▼ −6.73% | ▼ −5.50% | $11.03 (+12.44%) |
May 7, 2026 24w ago | S-3 | $10.14 $10.79 | ▲ +6.41% | ▲ +6.18% | $11.03 (+8.78%) |
Mar 18, 2026 31w ago | Press Release | $8.98 $8.61 | ▼ −4.12% | ▼ −2.38% | $11.03 (+22.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers